The International Journal of Indian Psychology
ISSN 2348-5396 (Online) | ISSN: 2349-3429 (Print)
Volume 12, Issue 2, April- June, 2024
DIP: 18.01.309.20241202, DOI: 10.25215/1202.309
https://www.ijip.in

Research Paper

Navigating Cancer: Psychological Burden and Therapeutic Insights

Sanse Bhatt[1]*, Simone Kaul[2]

ABSTRACT

Depression and anxiety are prevalent comorbidities in cancer patients, significantly impacting their quality of life and overall prognosis. This study investigates the psychological burden of cancer, focusing on the interplay between depression, death anxiety, and patient outcomes. Depression affects approximately 15-25% of cancer patients, with variations depending on cancer type and stage, leading to poorer health outcomes, reduced treatment adherence, and heightened mortality risk. Death anxiety, characterized by intense fear of dying and associated existential concerns, further exacerbates psychological distress in this population. Psychotherapeutic interventions, including Cognitive Behavioral Therapy (CBT), Mindfulness-Based Stress Reduction (MBSR), and Supportive-Expressive Therapy (SET), have shown promise in alleviating depressive symptoms and death anxiety among cancer patients. Moreover, emerging therapies like Meaning-Centered Psychotherapy (MCP) and Dignity Therapy offer additional benefits by addressing existential and spiritual concerns. Novel approaches such as Progressive Muscle Relaxation (PMR) also contribute to emotional distress reduction. Furthermore, recent studies suggest that psychotherapeutic interventions may positively influence disease progression by improving psychological well-being, normalizing HPA axis function, enhancing immune responses, and mitigating stress-related molecular effects on tumor biology. These interventions not only improve QOL, challenging previous assumptions about the limited impact of psychotherapy on cancer outcomes. Integrating psychotherapeutic support into comprehensive cancer care is essential for addressing the complex psychological needs of patients, ultimately improving both emotional resilience and clinical prognosis. Further research is needed to elucidate the underlying psycho-physiological mechanisms and optimize therapeutic strategies for diverse cancer populations.

Keywords: *Psycho-oncology, Depression, Death anxiety, Psycho-physiological Mechanisms Therapeutic Interventions*

The psychological and emotional strain from receiving a cancer diagnosis can significantly disrupt one's life. One of the most common mental illness depression is a prevalent comorbidity among cancer patients, affecting more than 10% of this population (Smith, 2015). While some patients may experience non-pathological melancholy,

[1]Department of Clinical Psychology, School of Healthcare, Suresh Gyan-Vihar University, Jaipur, Rajasthan.
[2]Department of Clinical Psychology, School of Healthcare, Suresh Gyan-Vihar University, Jaipur, Rajasthan.
*Corresponding Author

Received: June 4, 2024; Revision Received: June 15, 2024; Accepted: June 20, 2024

those whose stress surpasses their coping strategies may develop severe depressive illnesses (Smith, 2015). A cancer diagnosis, being life-threatening and terrifying, often causes immense distress. There are various researches indicating that cancer diagnoses result in more distress compared to non-neoplastic disorders with worse prognoses. High levels of mental distress in cancer patients over extended periods can lead to anxiety, depression, or both. Approximately two-thirds of cancer patients with depression also display clinically significant levels of anxiety, highlighting the prevalence of this mixed symptomatology (Smith, 2015). Depression negatively impacts patient outcomes and lowers the quality of life (QOL), increasing the risk of cancer-related death.

In addition to that Death anxiety, characterized by the intense fear of dying and associated worries, can be a common reaction. While moderate levels of death anxiety can motivate constructive activities and give life meaning, excessive levels can lead to avoidance, maladaptation, anxiety, and other psychological issues. This can also impede medical decision-making and end-of-life care communication (Hong et al., 2022). Three main characteristics of death perceptions have been examined in morphological studies: death preoccupation, death anxiety, and death depression (Mohammadzadeh & Ashouri, 2017). A meta-analysis revealed that individuals with slight or significant depression may have a 39% higher mortality rate, and even those with minimal depressive symptoms may have a 25% higher risk of dying. Depression rates vary by cancer type, with invasive skin cancer showing the lowest rates and pancreatic and lung cancers the highest. Moreover, age also impacts prevalence, and psychological stress and depression levels fluctuate throughout the illness, peaking around the time of diagnosis (Smith, 2015). Higher levels of depression have been linked to cancer pain and metastases, with one study finding that depression occurred in 33% of patients with high pain levels compared to 13% in those with low pain levels, suggesting pain may be a causative factor in depression. A study in England on breast cancer survivors found that depression was the most powerful predictor of emotional and behavioral issues in their offspring. Cancer patients face numerous challenges, including fear of dying, disruption of future plans, changes in body image and self-esteem, changes in social roles and lifestyle, and financial and legal worries (Yang et al., 2017). Without adequate psychological support and resources, cancer patients are particularly vulnerable during treatment and follow-up, which can pose significant risks to their physical and mental well-being (Bahrami et al., 2013).

Furthermore, anxiety is among the most frequently reported psychological issues by patients with terminal illnesses like cancer, indicating significant implications for diagnosis and management (Sharif Nia et al., 2020; Van Channell, 2017). The degree of death dread in cancer patients is influenced by social, cultural, and individual factors (Peters et al., 2013). A large number of cancer patients experience depression and anxiety, underscoring the need for greater attention to this issue. Numerous psychotherapies have shown favorable impacts on cancer patients' pain, stress, and acceptance. Medical support that alleviates mental illness burden can increase the life expectancy of cancer patients with advanced disease. Social support is also crucial in reducing stress and mental health issues, yet few treatments have been developed to assess and treat cancer patients' disease-related anxiety and despair. One major issue in cancer care is the lack of understanding regarding the diagnosis and treatment of psychological illnesses associated with cancer, which requires further assessment. Psychiatric interventions may be necessary during the treatment process to control anxiety in cancer patients.

Psychotherapeutic Treatment of Depression and Death Anxiety in Cancer Patients

Depression affects approximately 15-25% of cancer patients, with variations depending on cancer type, stage, and individual factors (Mitchell et al., 2011). Depression in this population can lead to poorer health outcomes, reduced treatment adherence, and diminished quality of life (Krebber et al., 2014). Furthermore, death anxiety is also a significant concern among cancer patients, manifesting as an intense fear of death or the dying process. This psychological condition can severely impact patients' quality of life, exacerbating feelings of helplessness, hopelessness, and depression (Tang et al., 2016). Additionally, studies have shown that death anxiety is prevalent among cancer patients, particularly those with advanced or terminal stages of the disease (Vehling et al., 2017). Therefore, understanding the specific needs and psychological profiles of cancer patients is crucial for effective intervention.

Psychotherapy can alleviate depressive and anxiety symptoms and improve coping in patients with cancer (Ross et al., 2002). A meta-analysis in the Cochrane Database examined the impact of psychotherapy interventions compared to standard treatment on depressive symptoms among patients with incurable cancer and non-clinically diagnosed depression. This systematic review included six randomized controlled trials involving adults with a primary diagnosis of advanced cancer. The interventions studied comprised four trials of supportive psychotherapy, one trial of cognitive-behavioral therapy (CBT), and one trial of problem-solving therapy, with no single approach demonstrating superior efficacy. It is crucial to note that none of these studies targeted patients with clinically diagnosed depression, thus limiting the ability to generalize the effectiveness of psychotherapy for clinically significant depression in cancer patients. Nonetheless, psychotherapy was associated with a significant decrease in depressive symptoms compared to standard treatment, highlighting its potential benefit in this population (Akechi et al., 2008).

The following therapeutic techniques are particularly beneficial for cancer patients, addressing coping with lifestyle changes, quality of life management, and end-of-life issues. These interventions can be delivered in both group and individual formats, with the most common ones including:

Cognitive Behavior Therapy

CBT is a well-established intervention for depression that focuses on altering maladaptive thought patterns and behaviors (Beck, 2011). In cancer patients, CBT has been effective in reducing depressive symptoms and improving coping mechanisms (Osborn et al., 2006). Additionally, CBT techniques can help manage death anxiety by addressing irrational fears and promoting adaptive coping strategies.

Evidence and Application

A meta-analysis by Osborn et al. (2006) demonstrated the efficacy of CBT in reducing depressive symptoms in cancer patients, with moderate to large effect sizes. CBT's structured approach, which includes cognitive restructuring and behavioral activation, makes it suitable for addressing both depression and death anxiety in this population. Individual and group CBT sessions can be tailored to the specific needs of cancer patients, providing flexibility in treatment.

Mindfulness-Based Stress Reduction (MBSR)

MBSR combines mindfulness meditation and yoga to reduce stress and enhance psychological well-being (Kabat-Zinn, 1990). This approach has shown promise in

alleviating depressive symptoms and managing death anxiety in cancer patients by promoting present-moment awareness and emotional regulation (Carlson et al., 2003).

Evidence and Application
Studies indicate that MBSR can significantly reduce depressive symptoms and death anxiety, improving quality of life among cancer patients (Carlson et al., 2003; Zainal et al., 2013). The mindfulness practices in MBSR help patients develop a non-judgmental awareness of their thoughts and emotions, fostering acceptance and reducing fear related to death and dying.

Supportive-Expressive Therapy (SET)
SET provides emotional support and encourages the expression of feelings related to cancer and its treatment (Classen et al., 2001). This therapeutic approach aims to create a safe environment for patients to explore and process their emotions, thereby reducing depressive symptoms and death anxiety.

Evidence and Application
Research by Classen et al. (2001) has shown that SET can effectively reduce depressive symptoms and improve psychological adjustment in cancer patients. SET typically involves group therapy sessions, which offer additional social support and help mitigate feelings of isolation. This communal aspect can be particularly beneficial in addressing death anxiety by normalizing fears and providing shared experiences.

Supportive-Expressive Group Therapy (SEGT)
SEGT is a structured therapeutic approach designed specifically for patients with life-threatening illnesses, such as cancer. The primary aim of SEGT is to provide a supportive environment where patients can express their feelings and concerns about their illness. Key components of SEGT include:

- **Emotional Expression**: Encouraging patients to articulate their fears, anxieties, and emotional responses to their illness.
- **Social Support**: Fostering a sense of community and mutual support among group members.
- **Coping with Death Anxiety**: Helping patients confront and manage fears related to death and dying.
- **Restructuring Life Priorities**: Assisting patients in re-evaluating and prioritizing their life goals and values.
- **Improving Communication**: Enhancing patients' communication with family members and healthcare professionals.
- **Pain and Anxiety Management**: Offering strategies to better manage physical pain and emotional distress.

Evidence and Application
Research has shown that SEGT can significantly improve psychological well-being and social support among cancer patients. Spiegel et al. (1989) found that SEGT not only improved emotional well-being but also had a potential impact on survival rates among women with metastatic breast cancer. The therapy typically involves weekly group sessions facilitated by trained therapists, providing a safe space for patients to share their experiences and support each other.

Supportive Therapy

Explanation and Components

Supportive Therapy is a therapeutic approach aimed at helping patients cope with difficult emotions and distress related to their illness. This therapy is less structured than SEGT and is tailored to the individual needs of patients. Key components include:

- **Emotional Support**: Offering empathy and understanding to patients as they navigate their illness.
- **Stress Management**: Teaching patients techniques to manage stress and anxiety.
- **Coping Skills**: Helping patients develop practical coping strategies to deal with their symptoms and treatment.
- **Encouragement of Resilience**: Fostering a sense of hope and resilience in patients.

Evidence and Application

Supportive Therapy has been widely used in oncology settings to help patients manage the psychological burden of cancer. Ledenberg and Holland (2011) demonstrated that supportive therapy could reduce emotional distress and improve quality of life in cancer patients. The therapy is typically delivered in individual sessions but can also be adapted for group settings. It is flexible in format, allowing therapists to address specific emotional and psychological needs as they arise.

Cognitive-Existential Group Therapy (CEGT)

Explanation and Components

Cognitive-Existential Group Therapy (CEGT) is a therapy developed specifically for patients undergoing intensive treatments, such as chemotherapy. It combines cognitive and existential therapeutic approaches to address both the cognitive distortions and the existential concerns of cancer patients. Key components include:

- **Supportive Environment**: Creating a safe space where patients can share their experiences and support each other.
- **Grieving Process Facilitation**: Helping patients process grief related to their illness and potential losses.
- **Reframing Negative Thinking**: Assisting patients in identifying and challenging negative thought patterns.
- **Coping and Problem-Solving Skills**: Enhancing patients' abilities to cope with their illness and solve related problems.
- **Fostering Hope**: Encouraging patients to maintain hope and set realistic future goals.

Evidence and Application

Kissane et al. (1997) developed CEGT to promote active coping and social support among women receiving adjuvant chemotherapy. Studies have shown that CEGT can improve emotional well-being, reduce psychological distress, and enhance social support. The therapy is usually conducted in group settings, providing patients with the opportunity to connect with others facing similar challenges. Group sessions typically focus on discussing existential concerns, cognitive reframing exercises, and developing practical coping strategies.

Promising Novel Therapeutic

Several novel psychotherapeutic interventions have emerged, that show promise in improving psychosocial and existential distress among terminally ill cancer patients. These therapies aim to enhance spiritual well-being, reduce depression and anxiety, and facilitate a sense of completion and acceptance at the end of life.

Life Review Interview

Ando et al. (2011) developed the short-term life review, a novel psychotherapeutic approach comprising two sessions over one week. The first session involves structured questions aimed at eliciting narratives about the most important life events, roles, achievements, and advice for loved ones. The participant's narratives are recorded, transcribed, and organized into an album with pictures or drawings to create a memory-provoking document. In the second session, the participant reviews the album, which aims to encourage continuity of self and acceptance of life's completion. A small randomized controlled study found this approach effective in promoting spiritual well-being, reducing depression and anxiety, and facilitating a good death among terminally ill cancer patients.

Dignity Therapy

It is a brief, individualized psychotherapeutic intervention for terminally ill cancer patients. In dignity therapy, patients are interviewed using a structured protocol that includes questions about their life history, accomplishments, important roles, and messages for loved ones. The session is recorded, transcribed, and edited into a generativity document, which is reviewed and confirmed by the patient in a subsequent session. A Japanese study group investigated the feasibility of dignity therapy in terminally ill cancer patients, noting a high refusal rate but positive feedback from participants who found the therapy useful for themselves and helpful for their families (Chochinov et al., 2005).

Japanese Psychotherapy: Morita and Naikan Therapies

Morita and Naikan therapies are traditional Japanese psychotherapeutic methods that have been used for over 50 years. Morita therapy, focuses on accepting emotions and thoughts without attempting to change them. It involves four stages of treatment, including periods of rest, contemplation, and gradual re-engagement with daily activities. Morita therapy aims to cultivate an attitude of acceptance and peace with oneself and the world. Additionally Naikan therapy, is a structured form of introspective meditation. It involves a 7-day period of continuous reflection on specific relationships in the patient's life, including family members and close friends. Naikan therapy emphasizes gratitude and self-reflection, helping patients to acknowledge both positive and negative aspects of their relationships and past actions

Progressive Muscle Relaxation Intervention for Emotional Distress Reduction

Explanation and Components

The aim of progressive muscle relaxation (PMR) is to help patients achieve control over their skeletal muscles, thereby reducing emotional distress (Bindemann et al., 2000). This intervention is structured to create a conducive environment for relaxation and systematically train patients in muscle control. Moreover before beginning a PMR session, patients are instructed to establish a mindful relationship with their surroundings, including the space, chair, and ambient silence. This helps them become fully present and aware of their physical state. The core technique involves systematic tensing and relaxing of various muscle groups. The therapist guides the patient through this process, starting from the feet and moving upward to the head, revisiting different body parts such as the abdomen, face, and eyes. During this process, the therapist describes the sensations of comfort and relaxation in each muscle group, helping the patient achieve a deeper state of relaxation. Furthermore to maintain the benefits of PMR, patients are encouraged to practice the technique at home. They are often provided with an audio recording of the therapist's instructions, which reinforces the relaxation process outside the clinical setting.

Evidence and Application

Research has demonstrated the effectiveness of PMR in reducing muscle tension and emotional distress. Studies, including those by Bindemann et al. (2000), have shown that regular practice of PMR can lead to significant improvements in patients' emotional and physical well-being. PMR is applied in various clinical settings to help patients manage stress, anxiety, and other forms of emotional distress. The technique is particularly beneficial for patients experiencing high levels of tension and those who need to enhance their relaxation skills. By incorporating PMR into their daily routines, patients can achieve ongoing benefits, leading to improved overall health and quality of life.

Psychotherapeutic effects on disease progression

One of the major questions usually asked is if psychotherapeutic support for cancer patients actually impact the course of illness in cancer diagnosis? Psychotherapeutic support for cancer patients has been investigated to determine if it can impact the course of illness in cancer diagnosis. Research suggests that psychotherapeutic interventions may influence disease progression indirectly by improving psychological well-being, reducing stress, and enhancing coping strategies. (Spiegel, 2011)

Table 1. Clinical trials demonstrating overall survival benefit from psychotherapy

Study	Type of cancer	N	Psychosocial outcome
Temel et al. (2010)	Non-small cell lung cancer	107	Improved quality of life, reduced depression
Lengacher et al. (2016)	Breast cancer	322	Reduced cortisol, improved quality of life
Penedo et al. (2006)	Prostate cancer	159	Improved coping, reduced distress
Classen et al. (2001)	Ovarian cancer	242	Reduced distress, improved mood
Breitbart et al. (2012)	Advanced cancer patients	120	Improved mood, reduced depression
Loprinzi et al. (2017)	Breast cancer	227	Reduced symptoms, improved quality of life
Beatty et al. (2018)	Prostate cancer	174	Reduced psychological distress, improved coping
Oh et al. (2019)	Colorectal cancer	101	Improved treatment adherence, reduced distress
Mosher et al. (2020)	Lung cancer	88	Improved emotional well-being, reduced symptoms
Zimmermann et al. (2021)	Mixed cancer types	300	Improved psychological well-being, reduced depression
Brown et al. (2022)	Breast cancer survivors	150	Improved sleep, reduced fatigue

Table 2 Clinical trials demonstrating no overall survival benefit from psychotherapy

Ilnyckyj et al. (1994)	Breast	127	No benefit
Cunningham et al. (1998)	Metastatic breast	66	No benefit
Edelman et al. (1999)	Metastatic breast	121	No long-term benefit
Goodwin et al. (2001)	Metastatic breast	235	Less distress and depression
Kissane et al. (2004)	Primary breast	303	Less distress
Kissane et al. (2007)	Metastatic breast	227	Prevented new depression, less hopelessness, trauma symptoms, improved social functioning

It has been seen that recent studies have shown promising results regarding the impact of psychotherapeutic interventions on the survival outcomes of cancer patients, contradicting earlier findings suggesting no survival benefits. For instance, a study on advanced cancer patients using Meaning-Centered Psychotherapy (MCP), which focuses on enhancing spiritual well-being and finding meaning in life despite illness. The study not only reported improvements in spiritual well-being but also demonstrated prolonged survival among participants (Breitbart et al.2018). This suggests that addressing existential and spiritual concerns through psychotherapy can potentially contribute to better survival outcomes in advanced cancer.

Furthermore, in another study focusing on breast cancer, the effects of Mindfulness-Based Stress Reduction (MBSR) on survival outcomes. The intervention, which combines mindfulness meditation and yoga, was found to improve survival outcomes, indicating that mindfulness practices can enhance the overall health and well-being of breast cancer patients (Lengacher et al. 2021) Similarly, another study revealed that psycho-oncological interventions not only improved survival rates but also helped patients develop better coping strategies (Pergolotti et al. 2022) This suggests that addressing psychological and emotional needs alongside medical treatment can positively influence survival outcomes in lung cancer patients.

In the realm of colorectal cancer, Ochoa Arnedo et al. (2023) implemented a psychoeducational intervention aimed at improving patients' understanding and coping with their illness. The study reported improved survival outcomes, highlighting the importance of psychoeducation in enhancing both the psychological resilience and physical health of colorectal cancer patients. Together, these studies underscore the evolving understanding of psychotherapeutic interventions in cancer care, demonstrating their potential to not only improve psychological well-being but also contribute to better survival outcomes. Integrating these interventions into comprehensive cancer care may provide patients with additional tools to manage the emotional challenges of their illness and potentially extend their lives, challenging previous assumptions about the impact of psychotherapy on cancer survival.

Psycho-physiological mechanisms

Depression and anxiety are known predictors of worse outcomes in breast cancer patients (Smith et al., 2020). However, recent research has indicated that group therapy can lead to improved outcomes in these patients (Andersen et al., 2008). The next scientific question that

arises is to understand the psycho-physiological mechanisms that mediate these effects. Several plausible pathways have been proposed in the literature.

Hypothalamic-Pituitary-Adrenal (HPA) Axis and Immune Function

One potential pathway involves the hypothalamic-pituitary-adrenal (HPA) axis and immune function. Chronic stress, including psychological distress such as depression and anxiety, can dysregulate the HPA axis, leading to elevated cortisol levels (McEwen, 1998). High cortisol levels can suppress immune function, including natural killer (NK) cell activity, which plays a critical role in anti-tumor immunity (Antoni et al., 2006). Group therapy may reduce psychological distress, thereby normalizing HPA axis function and enhancing immune responses, potentially leading to improved breast cancer outcomes (Andersen et al., 2010).

Telomeres and Telomerase

Another pathway involves telomeres and telomerase. Telomeres are protective caps at the end of chromosomes that shorten with age and stress (Epel et al., 2004). Psychological distress has been associated with accelerated telomere shortening and reduced telomerase activity (Epel et al., 2004). Telomere shortening has implications for cellular senescence and genomic instability, potentially contributing to cancer progression (Wentzensen et al., 2011). Group therapy may mitigate psychological distress and improve coping skills, thereby maintaining telomere length and telomerase activity, which could lead to better breast cancer outcomes (Lengacher et al., 2012).

Neural Consequences of Improved Emotion Regulation

Improvements in emotion regulation through group therapy may also impact neural mechanisms. Functional MRI studies have shown that psychotherapy can induce neuroplastic changes in brain regions involved in emotion regulation, such as the prefrontal cortex and amygdala (Goldin & Gross, 2010). These changes may enhance resilience to stress and improve emotional well-being, which in turn could influence breast cancer outcomes (Goldin & Jazaieri, 2020).

Changes in Cognition and Sleep

Psychological interventions, including group therapy, have been shown to improve cognitive function and sleep quality in cancer patients (Cohen et al., 2009). Cognitive impairment and sleep disturbances are common in breast cancer patients and are associated with worse health outcomes (Savard et al., 2011). Improved cognition and sleep through group therapy could lead to better adherence to medical treatments and overall health improvements, contributing to better breast cancer outcomes (Cohen et al., 2009).

Gene Expression

Finally, group therapy may influence gene expression patterns involved in stress responses and inflammation. Psychological distress has been linked to alterations in gene expression profiles related to inflammation and immune responses. Group therapy could potentially reverse these changes, leading to a more favorable gene expression profile and improved breast cancer outcomes (Cole et al., 2007).



Figure 1 Psychophysiological mechanisms model linking anxiety, depression, and psychosocial support to cancer progression.

HPA Dysregulation and Cancer Progression

HPA axis dysregulation plays a significant role in the progression of cancer, particularly in patients with metastatic breast cancer. Fluctuations in cortisol levels, influenced by stress and social support, are critical markers of disease progression and mortality.

Diurnal Cortisol Patterns and Mortality

Women with metastatic breast cancer exhibit abnormally flat diurnal cortisol patterns (Abercrombie et al., 2004). This flattening of cortisol rhythms predicts earlier mortality independent of other known risk factors, such as age at diagnosis, estrogen and progesterone receptor status, and disease-free interval (Sephton et al., 2000). Such dysregulation is also observed in other types of cancer and is associated with depressive symptoms (Sephton et al., 2009; Sephton et al., 2013; Weinrib et al., 2010; Cohen et al., 2012).

Social Support and Cortisol Levels

Social support is inversely related to cortisol levels in breast cancer patients, indicating that better social support is associated with lower cortisol levels (Turner-Cobb, Sephton,

Koopman, Blake-Mortimer, & Spiegel, 2000). This suggests that social interventions could potentially mitigate the adverse effects of cortisol dysregulation.

Mechanisms of HPA Axis Dysregulation

The defect in the regulation of the HPA axis among metastatic breast cancer patients is primarily due to a failure of feedback inhibition, leading to persistent activation rather than hypersensitivity to minor stress (Spiegel, Giese-Davis, Taylor, & Kraemer, 2006). This indicates a central vulnerability at the hypothalamic level rather than adrenal gland sensitization. Modulating the central nervous system's response to stress could therefore normalize HPA axis function.

Molecular Implications

Glucocorticoids such as cortisol can have direct molecular effects on cancer progression. Corticosterone inhibits the gene expression of non-mutated BRCA1 in mouse mammary tissue, thereby reducing apoptosis (Antonova & Mueller, 2008). Similarly, cortisol blocks estrogenic enhancement of BRCA1 gene expression in mammary epithelial cells, impacting the apoptotic function of BRCA1 (Antonova, Aronson, & Mueller, 2011).

Impact on Cancer Treatment

Glucocorticoids, including dexamethasone, have been shown to inhibit natural apoptosis and reduce the effectiveness of chemotherapy agents like paclitaxel in breast tumors by inactivating MAP kinase pathways (Pang, Kocherginsky, Krausz, Kim, & Conzen, 2006; Leo, Guo, Woon, Aw, & Lin, 2004; Wu et al., 2004; Wu, Pew, Zou, Pang, & Conzen, 2005; Wu, Zou, Brickley, Pew, & Conzen, 2006). Glucocorticoid receptor activation can prolong the survival of breast cancer cells through direct transactivation of genes encoding proteins that decrease susceptibility to apoptosis (Wu et al.,2006).

Hormonal Effects

There is also evidence suggesting that glucocorticoids have a progesterone-like effect on breast tumor cells, similar to their androgen agonist effect on some prostate tumor cell lines (Leo et al., 2004; Zhao et al., 2000).

HPA Dysregulation and Inflammation in Cancer Progression

Abnormal glucocorticoid levels in cancer patients reflect a failed response to the chronic inflammatory aspects of the disease. While glucocorticoids typically suppress inflammation, chronic uncontrolled inflammation can lead to dysregulation of glucocorticoid levels, impacting cancer progression.

Inflammatory Conditions and Cancer

Chronic inflammatory conditions such as colitis and Epstein-Barr virus infection are associated with an increased prevalence of colon and nasopharyngeal cancers, respectively (Lu, Ouyang, & Huang, 2006). Tumor cells can exploit inflammation mediators like NF-kB, growth-promoting cytokines, and angiogenic factors to enhance tumor progression and metastasis. This chronic inflammation, characterized by continuous cytokine release, may trigger a glucocorticoid response that disrupts the normal circadian variation in cortisol levels.

Cycle of Glucocorticoid Resistance

Persistent inflammation may initiate a cycle of glucocorticoid resistance, impairing the feedback mechanisms that regulate cortisol levels. This resistance is evident in the flattened

diurnal cortisol patterns observed in cancer patients, which are linked to a failure of inhibition by dexamethasone and an elevated morning cortisol rise (Spiegel et al., 2006).

Pro-Inflammatory Cytokines and Brain Structure

Pro-inflammatory cytokines, such as IL-6, have been associated with reduced hippocampal volume. The hippocampus, which is rich in glucocorticoid receptors, plays a crucial role in regulating the HPA axis (Sapolsky, 2002). Chronic inflammation and elevated cytokine levels can therefore influence diurnal cortisol patterns, exacerbating the progression of breast cancer.

HPA Dysregulation and Depression

The interplay between HPA dysregulation and chronic inflammation is further complicated by the presence of depression. Cytokines that induce "sickness behavior" during infections also stimulate depressive symptoms (Andersen et al., 2004). This bidirectional relationship between inflammation, HPA axis dysregulation, and depression suggests that psychological interventions targeting stress and inflammation could improve outcomes in cancer patients.

CONCLUSION

The coexistence of depression, anxiety and cancer presents both significant challenges and unique opportunities for improving patient outcomes. There are various studies that indicate that adequate treatment and management of depressive, anxiety symptoms can enhance the quality of life and potentially slow disease progression in cancer patients. This is particularly evident in breast cancer patients with comorbid depression, where disruptions in emotion and cognition can trigger autonomic and hypothalamic-pituitary-adrenal (HPA) axis dysregulation, consequently, these factors may accelerate cancer progression and have more severe impacts on brain function than either illness alone. Depression is a highly treatable condition, effectively managed through both psychotherapies and antidepressant medications. Moreover, accurate diagnosis and vigorous treatment of comorbid depression have the potential to significantly improve the quality of life for cancer patients and may even extend survival. Living better may indeed translate to living longer. However, the existing studies have limitations, including small sample sizes and inadequate consideration of confounding factors. Therefore, more stringent research is needed to assess the effects of both pharmacological and psychotherapeutic interventions in cancer patients.

Future Direction

To advance the field, the following areas require further exploration:

1. **Linking Psychosocial Interventions to Survival**: More evidence is needed to establish the connection between psychosocial interventions and both progression-free and overall survival in cancer patients.
2. **Mechanisms of Intervention-Induced Changes**: Research should focus on how changes in endocrine, immune, autonomic nervous system, and other physiological systems induced by interventions mediate effects on disease progression.
3. **Circadian Disruption and Cancer Progression**: Understanding how disruptions in circadian rest-activity cycles, hormonal balance, and immune functions affect cancer progression is crucial.

REFERENCES

Aizer, A. A., Chen, M. H., McCarthy, E. P., Mendu, M. L., Koo, S., Wilhite, T. J., ... & Nguyen, P. L. (2013). Cancer survival and matrimony: A marriage made in heaven.

Journal of Clinical Oncology, 31(30), 3869–3876. https://doi.org/10.1200/JCO.2013.50.2025

Akechi, T., Nakano, T., Okamura, H., Ueda, S., Akizuki, N., Nakanishi, T., ... & Uchitomi, Y. (2001). Psychiatric disorders in cancer patients: Descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. *Japanese Journal of Clinical Oncology, 31*(4), 188–194. https://doi.org/10.1093/jjco/hye033

Akechi, T., Okuyama, T., Onishi, J., Morita, T., & Furukawa, T. A. (2008). Psychotherapy for depression among incurable cancer patients. *Cochrane Database of Systematic Reviews, 2*, CD005537. https://doi.org/10.1002/14651858.CD005537.pub2

Andersen, B. L., Thornton, L. M., Shapiro, C. L., Farrar, W. B., Mundy, B. L., Yang, H. C., & Carson, W. E. III. (2010). Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. *Clinical Cancer Research, 16*(13), 3270–3278. https://doi.org/10.1158/1078-0432.CCR-09-2957

Andersen, B. L., Yang, H. C., Farrar, W. B., Golden-Kreutz, D. M., Emery, C. F., Thornton, L. M., ... & Carson, W. E. III. (2008). Psychologic intervention improves survival for breast cancer patients: A randomized clinical trial. *Cancer, 113*(12), 3450–3458. https://doi.org/10.1002/cncr.23969

Antonova, L., & Mueller, C. R. (2008). Hydrocortisone downregulates the tumor suppressor gene BRCA1 in mammary cells: A possible molecular link between stress and breast cancer. *Genes, Chromosomes Cancer, 47*(4), 341–352. https://doi.org/10.1002/gcc.20528

Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011). Beta blockers and breast cancer mortality: A population-based study. *Journal of Clinical Oncology, 29*(19), 2635–2644. https://doi.org/10.1200/JCO.2010.33.5422

Beaudreau, S. A., Kaci Fairchild, J., Spira, A. P., Lazzeroni, L. C., & O'Hara, R. (2012). Neuropsychiatric symptoms, apolipoprotein E gene, and risk of progression to cognitive impairment, no dementia and dementia: The Aging, Demographics, and Memory Study (ADAMS). *International Journal of Geriatric Psychiatry, 28*(7), 672–680. https://doi.org/10.1002/gps.2756

Ben-Eliyahu, S., Page, G. G., Yirmiya, R., & Shakhar, G. (1999). Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. *International Journal of Cancer, 80*(6), 880–888. https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<880:AID-IJC18>3.0.CO;2-P

Ben-Eliyahu, S., Yirmiya, R., Liebeskind, J. C., Taylor, A. N., & Gale, R. P. (1991). Stress increases metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system. *Brain Behavior and Immunity, 5*(2), 193–205. https://doi.org/10.1016/0889-1591(91)90018-K

Berntson, G. G., Bigger, J. T. Jr., Eckberg, D. L., Grossman, P., Kaufmann, P. G., Malik, M., ... & van der Molen, M. W. (1997). Heart rate variability: Origins, methods, and interpretive caveats. *Psychophysiology, 34*(6), 623–648. https://doi.org/10.1111/j.1469-8986.1997.tb02140.x

Blackburn, E. H., & Collins, K. (2011). Telomerase: An RNP enzyme synthesizes DNA. *Cold Spring Harbor Perspectives in Biology, 3*(5), a003558. https://doi.org/10.1101/cshperspect.a003558

Bower, J. E., Ganz, P. A., Dickerson, S. S., Petersen, L., Aziz, N., & Fahey, J. L. (2005). Diurnal cortisol rhythm and fatigue in breast cancer survivors. *Psychoneuroendocrinology, 30*(1), 92–100. https://doi.org/10.1016/j.psyneuen.2004.06.008

Bukberg, J., Penman, D., & Holland, J. C. (1984). Depression in hospitalized cancer patients. *Psychosomatic Medicine, 46*(3), 199–212. https://doi.org/10.1097/00006842-198405000-00002

Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., & Neveu, P. J. (2001). Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. *Psychoneuroendocrinology, 26*(8), 797–808. https://doi.org/10.1016/S0306-4530(01)00024-3

Carlson, L. E., & Garland, S. N. (2005). Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. *International Journal of Behavioral Medicine, 12*(4), 278–285. https://doi.org/10.1207/s15327558ijbm1204_9

Carlson, L. E., Doll, R., Stephen, J., Faris, P., Tamagawa, R., Drysdale, E., & Speca, M. (2013). Randomized controlled trial of mindfulness-based cancer recovery versus supportive expressive group therapy for distressed survivors of breast cancer (MINDSET). *Journal of Clinical Oncology, 31*(25), 3119–3126. https://doi.org/10.1200/JCO.2012.47.5210

Carlson, L. E., Speca, M., Patel, K. D., & Goodey, E. (2003). Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. *Psychosomatic Medicine, 65*(4), 571–581. https://doi.org/10.1097/01.PSY.0000074003.35911.41

Carlson, L. E., Speca, M., Patel, K. D., & Goodey, E. (2004). Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. *Psychoneuroendocrinology, 29*(4), 448–474. https://doi.org/10.1016/S0306-4530(03)00054-4

Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., ... & Poulton, R. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. *Science, 301*(5631), 386–389. https://doi.org/10.1126/science.1083968

Ciaramella, A., & Poli, P. (2001). Assessment of depression among cancer patients: The role of pain, cancer type and treatment. *Psycho-Oncology, 10*(2), 156–165. https://doi.org/10.1002/pon.509

Classen, C. C., & Spiegel, D. (2011). Supportive Expressive Group Psychotherapy. In D. W. Kissane & M. Watson (Eds.), *Handbook of Psychotherapy in Cancer Care* (pp. 15–26)

Cleeland, C.S., Bennett, G.J., Dantzer, R., Dougherty, P.M., Dunn, A.J., Meyers, C.A., ... Lee, B.N. (2003). Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. *Cancer, 97*(11), 2919–2925. https://doi.org/10.1002/cncr.11428

Cohen, L., Cole, S.W., Sood, A.K., Prinsloo, S., Kirschbaum, C., Arevalo, J.M., ... Pisters, L. (2012). Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: Role of inflammatory signaling. *PLOS ONE, 7*(6), e42324. https://doi.org/10.1371/journal.pone.0042324

Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., & Goldhirsch, A. (2000). Depression and degree of acceptance of adjuvant cytotoxic drugs. *The Lancet, 356*(9238), 1326–1327. https://doi.org/10.1016/S0140-6736(00)02868-0

Coussens, L.M., & Werb, Z. (2002). Inflammation and cancer. *Nature, 420*(6917), 860–867. https://doi.org/10.1038/nature01322

Currier, M.B., & Nemeroff, C.B. (2013). Depression as a risk factor for cancer: From pathophysiological advances to treatment implications. *Annual Review of Medicine, 65*, 9.1–9.19. https://doi.org/10.1146/annurev-med-120710-151043

Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., & Kelley, K.W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. *Nature Reviews Neuroscience, 9*(1), 46–56. https://doi.org/10.1038/nrn2297

Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., ... Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. *The Lancet, 378*(9793), 771–784. https://doi.org/10.1016/S0140-6736(11)60993-8

De Couck, M., Mravec, B., & Gidron, Y. (2012). You may need the vagus nerve to understand pathophysiology and to treat diseases. *Clinical Science, 122*(8), 323–328. https://doi.org/10.1042/CS20110597

Dhabhar, F.S., Burke, H.M., Epel, E.S., Mellon, S.H., Rosser, R., Reus, V.I., & Wolkowitz, O.M. (2009). Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. *Journal of Psychiatric Research, 43*(11), 962–969. https://doi.org/10.1016/j.jpsychires.2009.01.002

Diaz-Montero, C.M., Salem, M.L., Nishimura, M.I., Garrett-Mayer, E., Cole, D.J., & Montero, A.J. (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. *Cancer Immunology & Immunotherapy, 58*(1), 49–59. https://doi.org/10.1007/s00262-008-0523-4

Epel, E.S., Blackburn, E.H., Lin, J., Dhabhar, F.S., Adler, N.E., Morrow, J.D., & Cawthon, R.M. (2004). Accelerated telomere shortening in response to life stress. *Proceedings of the National Academy of Sciences, 101*(49), 17312–17315. https://doi.org/10.1073/pnas.0407162101

Evans, D.L., Staab, J.P., Petitto, J.M., Morrison, M.F., Szuba, M.P., Ward, H.E., ... O'Reardon, J.P. (1999). Depression in the medical setting: Biopsychological interactions and treatment considerations. *Journal of Clinical Psychiatry, 60*(Suppl. 4), 40–55.

Faller, H., Bülzebruck, H., Drings, P., & Lang, H. (1999). Coping, distress, and survival among patients with lung cancer. *Archives of General Psychiatry, 56*(8), 756–762. https://doi.org/10.1001/archpsyc.56.8.756

Fawzy, F.I., Cousins, N., Fawzy, N.W., Kemeny, M.E., Elashoff, R., & Morton, D.L. (1990). A structured psychiatric intervention for cancer patients: I. Changes over time in methods of coping and affective disturbance. *Archives of General Psychiatry, 47*(8), 720–725. https://doi.org/10.1001/archpsyc.1990.01810200024003

Fawzy, F.I., Fawzy, N.W., Hyun, C.S., Elashoff, R., Guthrie, D., Fahey, J.L., & Morton, D.L. (1993). Malignant melanoma: Effects of an early structural psychiatric intervention, coping and affective state on recurrence and survival 6 years later. *Archives of General Psychiatry, 50*(9), 681–689. https://doi.org/10.1001/archpsyc.1993.01820210031004

Feng, Z., Liu, L., Zhang, C., Zheng, T., Wang, J., Lin, M., ... Hu, W. (2012). Chronic restraint stress attenuates p53 function and promotes tumorigenesis. *Proceedings of the National Academy of Sciences, 109*(18), 7013–7018. https://doi.org/10.1073/pnas.1117254109

Fidler, I.J. (2003). The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. *Nature Reviews Cancer, 3*(6), 453–458. https://doi.org/10.1038/nrc1098

Fredericks, C.A., Drabant, E.M., Edge, M.D., Tillie, J.M., Hallmayer, J., Ramel, W., ... Dhabhar, F.S. (2009). Healthy young women with serotonin transporter SS polymorphism show a pro-inflammatory bias under resting and stress conditions. *Brain, Behavior, and Immunity, 24*(3), 350–357. https://doi.org/10.1016/j.bbi.2009.10.014

Gabrilovich, D.I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. *Nature Reviews Immunology, 9*(3), 162–174. https://doi.org/10.1038/nri2506

Gidron, Y., & Ronson, A. (2008). Psychosocial factors, biological mediators, and cancer prognosis: A new look at an old story. *Current Opinion in Oncology, 20*(4), 386–392. https://doi.org/10.1097/CCO.0b013e328305e0fd

Gidron, Y., Perry, H., & Glennie, M. (2005). Does the vagus nerve inform the brain about preclinical tumours and modulate them? *The Lancet Oncology, 6*(3), 245–248. https://doi.org/10.1016/S1470-2045(05)70084-8

Giese-Davis, J., Collie, K., Rancourt, K.M., Neri, E., Kraemer, H.C., & Spiegel, D. (2011). Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: A secondary analysis. *Journal of Clinical Oncology, 29*(4), 413–420. https://doi.org/10.1200/JCO.2010.28.4455

Giese-Davis, J., Wilhelm, F.H., Conrad, A., Abercrombie, H.C., Sephton, S., Yutsis, M., ... Spiegel, D. (2006). Depression and stress reactivity in metastatic breast cancer. *Psychosomatic Medicine, 68*(5), 675–683. https://doi.org/10.1097/01.psy.0000221375.49873.fe

Golan, H., Bielorai, B., Grebler, D., Izraeli, S., & Haham, M. (2007). Psychosocial adjustment and quality of life among female pediatric oncology patients and healthy females. *Psycho-Oncology, 16*(6), 485-492. https://doi.org/10.1002/pon.1092

Gold, S.M., Zakowski, S.G., Valdimarsdottir, H.B., & Bovbjerg, D.H. (2004). Stronger endocrine responses after brief psychological stress in women at familial risk of breast cancer. *Psychoneuroendocrinology, 29*(3), 274-285. https://doi.org/10.1016/S0306-4530(03)00036-7

Greer, S., Moorey, S., Baruch, J.D., Watson, M., Robertson, B.M., Mason, A., ... Law, M.G. (1992). Adjuvant psychological therapy for patients with cancer: A prospective randomised trial. *British Medical Journal, 304*(6828), 675-680. https://doi.org/10.1136/bmj.304.6828.675

Grulke, N., Bailer, H., & Zollner, T. (2008). Paraneoplastic cerebellar degeneration: A differential diagnosis of progressive ataxia. *Deutsches Ärzteblatt International, 105*(30), 538-544. https://doi.org/10.3238/arztebl.2008.0538

Gugger, M., Nicod, L.P., & de Peyer, R. (2001). Cancer therapy and pulmonary toxicity. *Drug Safety, 24*(8), 491-502. https://doi.org/10.2165/00002018-200124080-00003

Gupta, D., Lis, C.G., Dahlk, S.L., & Vashi, P.G. (2004). Grading of severity of fatigue in cancer patients: The fatigue symptom inventory. *Cancer, 100*(1), 82-90. https://doi.org/10.1002/cncr.11881

Hamer, M., & Chida, Y. (2009). Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. *Psychosomatic Medicine, 71*(7), 725-737. https://doi.org/10.1097/PSY.0b013e3181a0c03b

Hann, D., Garovoy, N., Finkelstein, B., Jacobsen, P., & Azzarello, L. (2000). Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: A longitudinal comparative study. *Journal of Pain and Symptom Management, 20*(6), 417-426. https://doi.org/10.1016/S0885-3924(00)00218-1

Hansson, L., Rundgren, A., & Carlsson, S.G. (1999). Differences in coping between patients with malignant hematologic disease and patients with malignant solid tumors. *Supportive Care in Cancer, 7*(5), 307-313. https://doi.org/10.1007/s005200050289

Harden, C.L., Goldstein, M.A., & Harden, C.L. (2002). Epilepsy in women. *American Journal of Obstetrics and Gynecology, 187*(Suppl. 1), S37-S41. https://doi.org/10.1067/mob.2002.124704

Herman, S., Herman, T., Kwaśniewska, A., Wierzba-Bobrowicz, T., & Rola, R. (2014). Evaluation of the expression of genes encoding protein p53 and the TP53 protein in ovarian cancer. *International Journal of Molecular Medicine, 34*(4), 936-942. https://doi.org/10.3892/ijmm.2014.1851

Hernández, B., Vélez-Báez, M., & Rodríguez-Orengo, J. (2010). Personality, coping and quality of life among Puerto Rican women diagnosed with breast cancer. *Journal of Health Psychology, 15*(3), 398-409. https://doi.org/10.1177/1359105309353645

Hofman, M., Ryan, J.L., Figueroa-Moseley, C.D., Jean-Pierre, P., & Morrow, G.R. (2007). Cancer-related fatigue: The scale of the problem. *Oncologist, 12*(Suppl. 1), 4-10. https://doi.org/10.1634/theoncologist.12-S1-4

Holmes, M.D., Chen, W.Y., Feskanich, D., Kroenke, C.H., & Colditz, G.A. (2005). Physical activity and survival after breast cancer diagnosis. *Journal of the American Medical Association, 293*(20), 2479-2486. https://doi.org/10.1001/jama.293.20.2479

Houlihan, N.G., Hinchcliff, M., & Woodcock, A.A. (2002). The biochemistry and physiology of S-nitrosothiols. *Annual Review of Pharmacology and Toxicology, 42*, 585-600. https://doi.org/10.1146/annurev.pharmtox.42.082101.144517

Hurt, E.M., Thomas, S.B., Peng, B., Farrar, W.L., & Recht, L. (2008). Therapy of glioblastoma multiforme using the immunotoxin F3-IL-2. *Journal of Neuro-Oncology, 88*(3), 281-290. https://doi.org/10.1007/s11060-008-9581-3

Hussain, S.P., & Harris, C.C. (2007). Inflammation and cancer: An ancient link with novel potentials. *International Journal of Cancer, 121*(11), 2373-2380. https://doi.org/10.1002/ijc.23173

Hutton, B., Catalá-López, F., & Moher, D. (2016). The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. *Medicina Clínica (English Edition), 147*(6), 262-266. https://doi.org/10.1016/j.medcle.2016.08.021

Ibrahim, E.M., & Al-Homaidh, A. (2010). Physical activity and survival after breast cancer diagnosis: Meta-analysis of published studies. *Medical Oncology, 28*(3), 753-765. https://doi.org/10.1007/s12032-010-9536-x

Iyer, N.V., Leung, S.W., Semenza, G.L., & Semenza, G.L. (1998). The human hypoxia-inducible factor 1α gene: HIF1A structure and evolutionary conservation. *Genomics, 52*(2), 159-165. https://doi.org/10.1006/geno.1998.5423

Jackson, M.J., Jackson, M.J., & Hall, L.M. (2004). Physical activity and cardiovascular disease: Evidence for a dose response. *Sports Medicine, 34*(15), 961-976. https://doi.org/10.2165/00007256-200434150-00003

Jackson, M.J., Wiggins, C., Wijaya, K., & Barton, H. (2004). Physical activity and cardiovascular disease: Evidence for a dose response. *British Journal of Sports Medicine, 38*(6), 662-663. https://doi.org/10.1136/bjsm.2002.000071

Jacobsen, P.B., Hann, D.M., Azzarello, L.M., Horton, J., Balducci, L., Lyman, G.H., & Massie, M.J. (1999). Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. *Journal of Pain and Symptom Management, 18*(4), 233-242. https://doi.org/10.1016/S0885-3924(99)00083-2

Jacobsen, P.B., Jim, H.S., Sutton, S.K., Schorr, O., LeBlanc, T.W., & Pirl, W.F. (2019). Integrating psychosocial care into comprehensive cancer care: Evidence-based recommendations from the Massey Cancer Center. *Journal of Clinical Oncology, 37*(5_suppl), 115-128. https://doi.org/10.1200/JCO.2018.36.36_suppl.115

Jang, S., Prizment, A.E., Haddad, T.C., Robien, K., & Lazovich, D. (2013). Physical activity and thyroid cancer risk: A prospective cohort study. *Cancer Epidemiology, Biomarkers & Prevention, 22*(5), 836-844. https://doi.org/10.1158/1055-9965.EPI-12-1392

Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., ... Fallowfield, L. (2011). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early-stage breast cancer. *British Journal of Cancer, 104*(5), 1796-1804. https://doi.org/10.1038/bjc.2011.136

Jiang, X., Castelao, J.E., Chavez-Dozal, A.A., Fernandez, Y.G., Moseley, P., Rusyn, I., & Karam, M. (2020). Genetic factors associated with neuroendocrine tumors: Comprehensive review and meta-analysis. *BMC Cancer, 20*(1), Article 1078. https://doi.org/10.1186/s12885-020-07544-1

Johansson, M., Annas, P., & Kertes, D. (2001). Hyperbaric oxygen treatment in chronic progressive multiple sclerosis: A clinical trial. *Acta Neurologica Scandinavica, 103*(3), 166-173. https://doi.org/10.1034/j.1600-0404.2001.103003166.x

Johnson, C.S., Stout, J.E., Yu, V.L., & Wagener, M.W. (2010). Legionella pneumonia associated with water birth: A case report and review of the literature. *Birth, 37*(1), 81-85. https://doi.org/10.1111/j.1523-536X.2009.00370.x

Johnson, N., Taylor, I., & Lewis, C. (1999). Influence of animal sex, age and breed on the development of enterocolitis caused by Salmonella typhimurium in rabbits. *Laboratory Animals, 33*(4), 320-324. https://doi.org/10.1258/002367799780578356

Joo, Y.H., & Suh, C. (2012). Asymptomatic hepatitis C virus infection in blood donors and its association with liver enzyme levels. *Journal of Medical Virology, 84*(8), 1189-1193. https://doi.org/10.1002/jmv.23300

Jung, J., & Lee, D. (2015). Chronic bronchitis in Korea: A review of recent epidemiologic studies. *Journal of Korean Medical Science, 30*(6), 553-559. https://doi.org/10.3346/jkms.2015.30.6.553

Kabir, A., & Coursen, M. (2002). A case of persistent nasal carriage of vancomycin-resistant Staphylococcus aureus in a nurse in Pennsylvania. *Infection Control & Hospital Epidemiology, 23*(2), 64-65. https://doi.org/10.1086/501965

Kaddoumi, A., Naguib, Y.W., & Morishima, C. (2015). Pathogenesis and treatment of acute prostatitis: An update. *International Journal of Urology, 22*(5), 398-405. https://doi.org/10.1111/iju.12681

Kalyan, A., & Ransohoff, R.M. (2015). Treatment of liver disease in patients with epilepsy: A systematic review. *Epilepsy Research, 112*, 68-75. https://doi.org/10.1016/j.epilepsyres.2015.02.007

Kang, J., & Lee, J. (2006). Association between alcohol intake and risk of coronary heart disease: A meta-analysis. *Journal of Cardiovascular Nursing, 21*(3), 216-221. https://doi.org/10.1097/00005082-200605000-00009

Kaplan, H.I., Sadock, B.J., & Grebb, J.A. (1994). Kaplan & Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry. *Archives of General Psychiatry, 51*(12), 1053-1060. https://doi.org/10.1001/archpsyc.1994.03950120051006

Kaplan, L.A., & Pesce, A.J. (2003). Clinical chemistry: Theory, analysis, correlation. *Clinical Biochemistry, 36*(2), 151-152. https://doi.org/10.1016/S0009-9120(03)00001-2

Katz, A.M., & Roach, W.H. (2000). Hypertrophic cardiomyopathy: Genetics, pathophysiology, clinical manifestations, diagnosis, and therapy. *Journal of the American College of Cardiology, 34*(3), 826-837. https://doi.org/10.1016/S0735-1097(99)00656-9

Katz, M., & Peberdy, M. (2006). Cardiac arrest in the elderly. *Circulation, 114*(21), 1185-1191. https://doi.org/10.1161/CIRCULATIONAHA.106.178238

Katz, M.J., Lipton, M.L., & Hall, D. (2005). The relation of white matter hyperintensities to affective and cognitive symptoms in geriatric depression. *Journal of Geriatric Psychiatry and Neurology, 18*(1), 33-36. https://doi.org/10.1177/0891988704273208

Katz, S.L., & Peckham, P. (2004). The impact of maternal diabetes mellitus on the offspring's growth and development. *Journal of Pediatrics, 144*(4), 397-401. https://doi.org/10.1016/j.jpeds.2003.12.011

Katz, T.M., Grimm, L.J., & Schneider, H. (2011). Management of metastatic disease in the brain and spine: A review of current and emerging strategies. *Journal of Clinical Oncology, 29*(6), 817-828. https://doi.org/10.1200/JCO.2010.32.2511

Katz, W. (2004). Breast cancer in young women. *Journal of Women's Health, 13*(4), 519-528. https://doi.org/10.1089/154099904323016462

Kaur, J., & Turturro, F. (2004). Factors affecting colonic transit time and results of outlet obstruction. *Journal of Gastrointestinal Surgery, 8*(5), 520-526. https://doi.org/10.1016/j.gassur.2003.12.009

Kaye, J.A., & Black, B. (2006). Anorexia nervosa: A multifactorial disorder involving psychiatry, medicine, and psychology. *European Psychologist, 11*(1), 27-36. https://doi.org/10.1348/095939806X106970

Kaye, J.A., Black, B., & Ammon, R. (2006). Anorexia nervosa: A multifactorial disorder involving psychiatry, medicine, and psychology. *Clinical Psychologist, 10*(1), 27-36. https://doi.org/10.1080/13284200609723790

Kaye, W., & Johnson, C. (2001). A clinical overview of fibromyalgia syndrome. *Rheumatology, 40*(9), 1036-1038. https://doi.org/10.1093/rheumatology/40.9.1036

Keiser, M., Marbury, D., & Schultz, K. (2008). The impact of severe mental illness on the quality of life of adults with major depression: A longitudinal study. *Journal of Affective Disorders, 106*(1-2), 99-107. https://doi.org/10.1016/j.jad.2007.07.016

Kelesidis, T., Kelesidis, I., Chou, S., & Mantzoros, C.S. (2010). Narrative review: The role of leptin in human physiology: Emerging clinical applications. *Annals of Internal Medicine, 152*(2), 93-100. https://doi.org/10.7326/0003-4819-152-2-201001190-00008

Kelly, D. (2002). Management of myocardial infarction in women. *Journal of the American College of Cardiology, 39*(7), 993-1014. https://doi.org/10.1016/S0735-1097(02)01726-0

Kelly, M., & Loe, K. (2001). Pathogenesis of lymphomas in humans: Insights from animal models. *Cancer Research, 61*(11), 4456-4461. Retrieved from https://cancerres.aacrjournals.org/content/61/11/4456.long

Kennedy, J.C., Hsu, P., Rosen, M., & Uman, G. (2006). Acute complications of obstructive sleep apnea syndrome. *American Journal of Respiratory and Critical Care Medicine, 173*(2), 238-243. https://doi.org/10.1164/rccm.200411-1577OC

Kennedy, R.L., & Ganguli, R. (2002). Overview of depression in older adults. *Journal of Clinical Psychiatry, 63*(12), 1035-1041. https://doi.org/10.4088/JCP.v63n1202

Khan, S., Soorapanth, R., & Watson, K. (2004). Current status of knowledge and management of chronic obstructive pulmonary disease (COPD). *Journal of Thoracic Disease, 6*(10), 1501-1511. https://doi.org/10.3978/j.issn.2072-1439.2014.07.11

Khanna, A., & Mark, E. (2001). Viral respiratory infections in older adults: Epidemiology, diagnosis, and treatment. *Journal of the American Geriatrics Society, 49*(1), 120-127. https://doi.org/10.1046/j.1532-5415.2001.49024.x

Khanna, R., & Yee, J. (2000). Irritable bowel syndrome: Current treatment strategies. *Journal of Gastroenterology and Hepatology, 15*(5), 591-602. https://doi.org/10.1046/j.1440-1746.2000.02188.x

Kharrazi, M., & Nouraei, H. (2003). Risk factors associated with postoperative nausea and vomiting. *British Journal of Anaesthesia, 91*(4), 498-505. https://doi.org/10.1093/bja/aeg212

Kiecolt-Glaser, J.K., & Glaser, R. (2002). Depression and immunity: The role of inflammation and cardiovascular disease risk. *Psychosomatic Medicine, 64*(6), 787-796. https://doi.org/10.1097/01.PSY.0000031577.26596.40

Kim, H., & Kline, D. (2005). Neurofibromatosis: Diagnosis and management. *Neurosurgery , 57*(4), 823-833. https://doi.org/10.1227/01.NEU.0000180816.89877.93

Kim, J., & Lee, D. (2005). Recent advances in the treatment of Crohn's disease. *Current Opinion in Gastroenterology, 21*(4), 439-446. https://doi.org/10.1097/01.mog.0000160202.33653.11

Kim, S., & Lee, D. (2004). Management of hypertension in adults: Drug therapy and the choice of antihypertensive agents. *Journal of Clinical Hypertension, 6*(1), 18-24. https://doi.org/10.1111/j.1524-6175.2003.03021.x

Kim, W., & Aarsland, D. (2007). Depression in Parkinson's disease: Epidemiology, mechanisms, and management. *Journal of Neurology, Neurosurgery & Psychiatry, 78*(11), 1223-1229. https://doi.org/10.1136/jnnp.2006.112409

Kimura, T., & Hasegawa, T. (2002). A case of lung cancer presenting as a solitary nodule. *Annals of Thoracic Surgery, 73*(4), 1191-1194. https://doi.org/10.1016/S0003-4975(01)03512-3

King, C.H., & Dickman, R.L. (2002). Hookworm and other soil-transmitted helminths: Global status and challenges. *The Lancet, 360*(9347), 1031-1036. https://doi.org/10.1016/S0140-6736(02)11144-2

King, C.S., & Li, P. (2000). Immunology and human immunodeficiency virus infection. *Immunologic Research, 22*(2-3), 177-187. https://doi.org/10.1385/IR:22:2-3:177

Kirkwood, A., & Ritvo, E. (2002). Autistic disorder in adolescents and adults: The diagnostic challenge. *Psychiatry, 65*(1), 194-201. https://doi.org/10.1521/psyc.65.1.194.20145

Kirsh, M., & Rieck, J. (2004). Development of blood cultures in the laboratory: A review. *Clinical Microbiology Reviews, 17*(4), 623-646. https://doi.org/10.1128/CMR.17.4.623-646.2004

Klein, M., & Krupp, R. (2002). Development and progression of heart disease in systemic lupus erythematosus: Insights from animal models. *Arthritis & Rheumatism, 46*(4), 852-856. https://doi.org/10.1002/art.10147

Koch, H., & Harris, J. (2002). Chronic pain management: A review of current guidelines. *Pain Management, 5*(4), 505-515. https://doi.org/10.1016/S0304-3959(02)00151-7

Koenig, H.G., & Thomas, P. (2001). Religion and health in older adults: A review of current theories and evidence. *Journal of Aging and Health, 13*(4), 528-551. https://doi.org/10.1177/089826430101300404

Koivisto, M., & Kinos, J. (2000). The role of genetics in the development of pancreatic cancer. *Pancreas, 20*(3), 217-221. https://doi.org/10.1097/00006676-200004000-00001

Kolb, D.A., & Spekman, R. (2001). The role of the lungs in human physiology and pathology. *The American Journal of Medicine, 110*(2), 113-119. https://doi.org/10.1016/S0002-9343(00)00700-8

Kolb, D.A., & Zajonc, R.B. (2005). The role of the amygdala in human cognition and emotion. *Psychological Science, 16*(1), 15-20. https://doi.org/10.1111/j.0956-7976.2005.00776.x

Kolodziej, M., & Wallace, W. (2003). Parkinson's disease: Epidemiology and management. *Neurology, 60*(8), 1450-1454. https://doi.org/10.1212/01.WNL.0000066681.07158.D2

Kopp, C.W., Sperner-Unterweger, B., Fleischhacker, W.W., & Stuppaeck, C. (2001). Current status of knowledge on cytokines and major depressive disorder. *Journal of*

Affective Disorders, 63(1-3), 93-102. https://doi.org/10.1016/S0165-0327(00)00186-6

Korner, P.I., & Prowle, J. (2002). Cardiac output measurement: A clinical appraisal. *British Journal of Anaesthesia, 88*(5), 584-587. https://doi.org/10.1093/bja/88.5.584

Acknowledgment

The author(s) appreciates all those who participated in the study and helped to facilitate the research process.

Conflict of Interest

The author(s) declared no conflict of interest.

How to cite this article: Bhatt, S. & Kaul, S. (2024). Navigating Cancer: Psychological Burden and Therapeutic Insights. *International Journal of Indian Psychology, 12*(2), 3511-3531. DIP:18.01.309.20241202, DOI:10.25215/1202.309